Scheelevägen 19 A
81 articles with Alligator Bioscience
Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development
Alligator Bioscience ("Alligator") (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy and Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietar
Aptevo Therapeutics and Alligator Bioscience Advancing the Bispecific 4-1BBx5T4 Antibody ALG.APV-527 Into Phase 1 Clinical Development
Aptevo Therapeutics Inc. and Alligator Bioscience provided an update on ALG.APV-527, a novel immunotherapeutic bispecific candidate intended for the treatment of multiple solid tumors expressing 5T4, a tumor-restricted antigen.
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it will present data from three immuno-oncology projects at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting, November 9-14, 202
Alligator Bioscience presents the CD40 antibody mitazalimab at the World Immunotherapy Congress 2020
Alligator Bioscience announced that its CD40 targeting antibody mitazalimab will be presented at the World Immunotherapy Congress, November 2-6, 2020.
The Phase I study with ATOR-1017 has progressed exceptionally well and in August we presented interim data that showed a good safety profile at clinically relevant dose levels.
Alligator Bioscience announced the decision to focus its resources on the two proprietary candidate drugs, ATOR-1017 and mitazalimab.
Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today the appointment of Gayle Mills as Chief Business Officer to lead the company's Business Development activities. Ms. Mills will be a member of the executive management team at Alligator Bioscience. Gayle Mills is a renowned business development professional wit
Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company launches a new concept for patient specific immunotherapy, called Neo-X-Prime . Alligator presents the concept at the scientific congress 11th World Bispecific Summit held September 22-24, 2020 . The new concept, based on Alligator's bispecific
Alligator Bioscience announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,774,150 which covers compositions of matter directed to Alligator's bispecific drug candidate ATOR-1015.
Alligator Bioscience presents an update regarding the Phase I study with the drug candidate ATOR-1015
Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today updated timelines indicating 3-6 months delay for the planned Phase Ib study with ATOR-1015, its tumor-localizing, bispecific CTLA-4 and OX40 antibody developed for treatment of metastatic cancer. As previously communicated, preliminary data from the ongoing Phase
Alligator Bioscience presents positive biomarker data demonstrating proof of mechanism in mitazalimab clinical Phase I study
Alligator Bioscience announced biomarker data from a recently performed clinical Phase I study of the drug candidate mitazalimab, its wholly owned CD40 antibody in development primarily for the treatment of pancreatic cancer.
Alligator Bioscience announced interim safety data from its ongoing clinical Phase I study of the drug candidate ATOR-1017, its wholly owned 4-1BB antibody in development for the treatment of metastasized cancer.
Alligator Bioscience will give status updates and details on the recent clinical development plans for the clinical drug candidates mitazalimab, ATOR-1015 and ATOR-1017 on a virtual R&D Day on August 27.
Alligator Bioscience invites to a virtual R&D Day on August 27 at 2:00 p.m. - 3:00 p.m., in which CEO Per Norlén and COO Malin Carlsson will give an update on the status and latest development steps in the company's clinical pipeline - focusing on the drug candidates mitazalimab, ATOR-1015 and ATOR-1017.
"With the new strategy announced in early April, we have put a stronger focus on Alligator's clinical development portfolio.
Alligator Bioscience announced the appointment of Marie Svensson as Chief Financial Officer, CFO. Marie Svensson has more than 20 years of experience from various financial positions in the high-tech industry and will be a member of Alligator's executive management team.
Alligator Bioscience and Scandion Oncology Sign Preclinical Agreement to Explore Combination Therapies for Chemotherapy and Immuno-oncology
Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Spotlight, Sweden: SCOL), today announced signing of a collaboration agreement. The two companies have agreed to explore the anti-tumor efficacy of the CD40 antibody mitazalimab (Alligator Bioscience) in combination with SCO-101 (Scandion Oncology) as an addition to
Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the company received an additional USD 0.5 million in a second installment of the upfront payment from the Chinese company Biotheus Inc. A first installment of USD 0.5 million was received in August 2019 in connection with Alligator entering into a licensing agr
Alligator Bioscience Presents Novel Supportive Phase I Data at ASCO for its CTLA-4 x OX40 Bispecific Drug Candidate ATOR-1015
Alligator Bioscience (Nasdaq Stockholm: ATORX), announces that the company today presents additional novel data from the ongoing Phase I clinical trial with the bispecific drug candidate ATOR-1015 developed as tumor-directed therapy for metastatic cancer, which further validates the potential of the drug. The presentation will be held a
In the midst of a pandemic, oncology-focused companies virtually unveil data at the American Association for Cancer Research (AACR) Annual Meeting.